TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Dose-response Trial Using FE 999049 in Japanese Women Undergoing in Vitro Fertilisation (IVF) / Intracytoplasmic Sperm Injection (ICSI) Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Women diagnosed with tubal infertility, unexplained infertility, infertility related to endometriosis stage I/II or with partners diagnosed with male factor infertility~* Women eligible for IVF and/or ICSI treatment~* Women aged 20-39 years~* Women with body mass index (BMI) of 17.5-32.0 kg/m2~Exclusion Criteria:~* Women with polycystic ovary syndrome (PCOS) associated with anovulation, endometriosis stage III/IV~* Women with history of recurrent miscarriage~* Women with contraindications to controlled ovarian stimulation with gonadotropins~* Women with three or more controlled ovarian stimulation cycles

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- FE 999049 6 µg (Type: EXPERIMENTAL): None
- FE 999049 9 µg (Type: EXPERIMENTAL): None
- FE 999049 12 µg (Type: EXPERIMENTAL): None
- FOLLISTIM 150 IU (Type: ACTIVE_COMPARATOR): follitropin beta

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Daily Dystonia Practice - A Trial to Investigate NT 201, the Duration of Treatment Effect After One Injection Session and in Long-term Treatment in Cervical Dystonia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) - total score at baseline \> / = 25 with TWSTRS - severity score \> / = 10 and TWSTRS - disability score \> / = 3~* Patients must be on a stable dose of other medications~* For pre-treated patients only: Source documentation of the last two consecutive injection sessions with botulinum neurotoxin type A and stable treatment response directly prior to trial entry~* For pre-treated patients only: At least 10 weeks must have passed between the last injection session of botulinum neurotoxin type A for cervical dystonia and the time of the baseline visit.~* For pre-treated patients only: The most recent injection session with botulinum neurotoxin for cervical dystonia must have been at a dose of ≤ 300 units of Botox® or Xeomin®, or ≤ 1,200 units Dysport®.~* Age \> / = 18 and \< 76 years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- NT 201 (50-300 Units) (Type: EXPERIMENTAL): NT 201 (Xeomin®, also know as IncobotulinumtoxinA or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Iron Supplementation in Schistosomiasis and Soil Transmitted Helminths Control Programmes in Zambia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:all schoolchildren, in grade 2 and 3, at four selected schools -~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Lower Lugol's Solution Concentration on Reducing the Adverse Symptoms of Chromoendoscopy With Iodine Staining

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SCREENING
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* patients in the high-risk population of ESCC;~* or general risk population of ESCC between 40 to 74 years old. Definition of high-risk population of ESCC is list in supporting information33.~Exclusion criteria included the following:~* with obvious abnormalities in stomach, confirmed by either white-light endoscopy (WLE) or pCLE, including gastric cancer, acute erosive and hemorrhagic gastritis, chronic atrophic gastritis, H. pylori infection and severe bile reflux gastritis;~* advanced esophageal carcinoma;~* known esophageal surgery or endoscopic treatment;~* known esophageal radiotherapy or chemotherapy;~* esophageal stenosis;~* food retention;~* allergy to iodine or fluorescein sodium;~* hyperthyroid;~* coagulopathy;~* acute bleeding;~* severe organ failure;~* pregnant or breastfeeding women.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 74 Years
- Healthy Volunteers: t

Study Arms:
- 1.2% Lugol's solution (Type: EXPERIMENTAL): This group patients were given concentrations of 1.2% Lugol's solution for chromoendoscopy.
- 1.0% Lugol's solution (Type: EXPERIMENTAL): This group patients were given concentrations of 1.0% Lugol's solution for chromoendoscopy.
- 0.8% Lugol's solution (Type: EXPERIMENTAL): This group patients were given concentrations of 0.8% Lugol's solution for chromoendoscopy.
- 0.6% Lugol's solution (Type: EXPERIMENTAL): This group patients were given concentrations of 0.6% Lugol's solution for chromoendoscopy.
- 0.4% Lugol's solution (Type: EXPERIMENTAL): This group patients were given concentrations of 0.4% Lugol's solution for chromoendoscopy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Histologically confirmed diagnosis of esophageal squamous cell carcinoma (ESCC)~2. Tumor progression during or after first-line treatment for advanced unresectable / metastatic ESCC~3. At least one measurable/evaluable lesion by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1~4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 prior to randomization~Key Exclusion Criteria:~1. Receipt of 2 or more prior systemic treatments for advanced/metastatic unresectable ESCC~2. History of gastrointestinal perforation and /or fistula or aorto-esophageal fistula within 6 months prior to randomization~3. Tumor invasion into organs located adjacent to the esophageal disease site (eg, aorta or respiratory tract) at an increased risk of fistula in the study treatment assessed by investigator~4. Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent drainage~5. Received prior therapies targeting programmed death 1 (PD-1) or programmed death ligand 1 (PD-L1)~6. Prior malignancy active within the previous 2 years (exceptions include the tumor under investigation in this trial, and locally recurring cancers that have undergone curative treatment, such as resected basal or squamous cell skin cancer, superficial bladder cancer or carcinoma in situ of the prostate, cervix or breast)~7. Active brain or leptomeningeal metastasis.~8. Has active autoimmune disease or history of autoimmune diseases at high risk for relapse~9. Known history of, or any evidence of interstitial lung disease, non-infectious pneumonitis, pulmonary fibrosis diagnosed based on imaging or clinical findings, or uncontrolled systemic diseases, including diabetes, hypertension, acute lung diseases, etc~10. Known history of Human Immunodeficiency Virus (HIV)~11. Has cardiovascular risk factors~12. Pregnant or breastfeeding woman.~NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tislelizumab (Type: EXPERIMENTAL): Tislelizumab on Day 1, given every 21 days
- Investigator chosen chemotherapy (ICC) (Type: ACTIVE_COMPARATOR): Paclitaxel on Day 1, given every 21 days or on a weekly schedule; OR Docetaxel on Day 1, given every 21 days; OR Irinotecan on Days 1 and 8, given every 21 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Heterozygous for F508del and a minimal function mutation (F/MF genotype)~* Forced expiratory volume in 1 second (FEV1) value \>=40% and \<=90% of predicted mean for age, sex, and height for participants currently receiving ELX/TEZ/IVA therapy; FEV1 \>=40% and \<=80% for participants not currently receiving ELX/TEZ/IVA~Key Exclusion Criteria:~* History of solid organ or hematological transplantation~* Hepatic cirrhosis with portal hypertension, moderate hepatic impairment (Child Pugh Score 7 to 9), or severe hepatic impairment (Child Pugh Score 10 to 15)~* Lung infection with organisms associated with a more rapid decline in pulmonary status~* Pregnant or breast-feeding females~Other protocol defined Inclusion/Exclusion criteria may apply

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ELX/TEZ/IVA (Type: ACTIVE_COMPARATOR): Following elexacftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) run-in period of 4 weeks, participants received ELX 200 milligram (mg) once daily (qd) /TEZ 100 mg qd/IVA 150 mg every 12 hours (q12h) in the treatment period for 52 weeks.
- VX-121/TEZ/D-IVA (Type: EXPERIMENTAL): Following ELX/TEZ/IVA run-in period of 4 weeks, participants received VX-121 20 mg qd/TEZ 100 mg qd/D-IVA 250 mg qd in the treatment period for 52 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of Eltrombopag or Intravenous Immune Globulin Before Surgery for Immune Thrombocytopenia Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary or secondary ITP;~* Platelet count below surgical platelet count threshold (50 x10\^9/L for minor surgery; 100 x 10\^9/L for major surgery);~* 18 years of age or older;~* On stable doses of concomitant ITP medications (i.e the dose administered has not changed) or no ITP medication for at least 2 weeks;~* At least 3-weeks lead time available between randomization and scheduled surgery;~* IVIG and Eltrombopag are acceptable ITP treatment options for this patient;~* Able to provide informed consent.~Exclusion Criteria:~* Pregnancy or breastfeeding;~* Treatment with IVIG within the last 2 weeks;~* Treatment with a thrombopoietin receptor agonist (eltrombopag or romiplostim) within the last 4 weeks;~* AST, ALT above 2X upper limit of normal;~* Bilirubin above 1.5X upper limit of normal in the absence of clinically benign liver disorder (eg. Gilberts syndrome);~* Deep vein thrombosis, myocardial infarction, thrombotic stroke or arterial thrombosis in the last 12 months;~* History of bone marrow reticulin or fibrosis;~* Known liver cirrhosis;~* Active malignancy (defined as requiring treatment or palliation within the last 6 months);~* Any additional laboratory test result, health related illness or other diagnosis which, in the opinion of the treating physician, may put the subject's health or safety at risk.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eltrombopag (Type: EXPERIMENTAL): Eltrombopag is a small molecule, non-peptide thrombopoietin (TPO) receptor agonist indicated for the treatment of thrombocytopenia in patients with chronic ITP who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy. TPO receptor agonists are an effective new class of medications that are non-immunogenic agonists of the TPO receptor (c-Mpl) and work by increasing platelet production in ITP patients.
- IVIG infusion (Type: ACTIVE_COMPARATOR): Intravenous immunoglobulin (IVIG) is used to rapidly increase platelet counts in ITP patients. IVIG is associated with a transient platelet count response in approximately 80% of patients, which occurs within 2 - 4 days. It is commonly used to improve platelet count numbers prior to surgery for patients with ITP.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Parecoxib for Treatment of Catheter Related Bladder Discomfort

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult (\>/=18)~2. Male or female~3. Undergoing catheterization after transurethral resection of bladder tumor (TURBT)~4. Under spinal anesthesia~5. Subject is American Society of Anesthesiologists (ASA) physical status 1 or 2.~Exclusion Criteria:~1. Patient who disagrees to participate this investigation~2. Patient with severe cardiovascular disease~3. Patient with small-sized foley catheter (less than 18 Fr.)~4. Patinets with bladder outflow obstruction~5. Patient with overactive bladder (frequency \>3 times,in the night or \>8 times in 24 h)~6. Patients with chronic renal failure~7. Patient with morbid obesity~8. Patient with medications for chronic pain~9. Patient with disturbance of the central nervous system

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Parecoxib (Type: EXPERIMENTAL): 40 mg of intravenous parecoxib (DYNASTAT )30 min before surgery
- Placebo (Type: PLACEBO_COMPARATOR): An equal volume of saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing Adjunctive Risperidone Versus Placebo in Major Depressive Disorder That Is Not Responding to Standard Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Understand and sign the informed consent form~* Age 18-65~* Healthy on the basis of Physical Exam~* Treatment with a single antidepressant 4 weeks prior to study start and willingness to maintain on stable dose of the same antidepressant throughout the study~* Current diagnosis of Major Depressive Disorder~* Judgement of the clinician that the subject has shown a sub-optimal response to the antidepressant~Exclusion Criteria:~* Presence of other serious medical illness(es)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical diagnosis of type 2 diabetes with confirmed HbA1c level \>10% at time of enrollment, regardless of prior or current treatment regimens, or time since diagnosis.~Exclusion Criteria:~1. Age \<18 as the feasibility and safety of this treatment regimen should be first established in the adult population; if successful, a subsequent pediatric study will be proposed;~2. Type 1 diabetes as purposefully withholding meal-time insulin is contraindicated;~3. Clinical state requiring inpatient admission/treatment;~4. Contraindication or strong cautions to any of the study medications:~   1. Creatinine above 1.4 mg/dl for women and 1.5 mg/dl for men (per metformin label)~  2. History of lactic acidosis (per metformin label)~  3. Advanced hepatic or cardiac disease (per metformin label)~  4. Age \>80 years (per metformin label)~  5. Chronic alcohol use (\>14 drinks/week)~  6. History of pancreatitis (per liraglutide label)~  7. Personal or family history of medullary thyroid cancer or MEN syndrome (per liraglutide label)~  8. Pregnancy and lactation (per liraglutide label)~5. Any serious or unstable medical condition as it would interfere with treatment assignment as well as outcome measurement;~6. Any scheduled elective procedures/surgeries;~7. Active infections, including osteomyelitis;~8. Not willing to participate, unable to keep projected appointments, unwillingness to receive injectable treatment; unwillingness to perform 7-point glucose profiles over 2 consecutive days the weeks prior to Randomization (visit 1)and the week prior to visit 6~9. Non English speaking.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Control: Metformin, Insulin Detemir, Insulin Aspart (Type: ACTIVE_COMPARATOR): Metformin titrated to max tolerated dose (at least 1000 mg/day); Insulin detemir titrated based on the study protocol; Insulin Aspart titrated by the physician
- Metformin, insulin determir, Liraglutide (Type: ACTIVE_COMPARATOR): Metformin titrated to max tolerated dose (at least 1000mg/day); Insulin detemir titrated based on the study protocol; Liraglutide titrated to max tolerated dose (at least 1.2 mg/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Intervention for Children With Vesicoureteral Reflux (RIVUR)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age at randomization: at least 2 months, but less than 6 years of age. Note that children as young as 1 month were screened for the study.~* Diagnosed first or second febrile or symptomatic UTI within 112 days prior to randomization~* Presence of Grade I- IV VUR based on radiographic voiding cystourethrogram (VCUG) performed within 112 days of diagnosis of index UTI.~* Appropriately treated index febrile or symptomatic UTI~Exclusion Criteria:~* Index UTI diagnosis more than 112 days prior to randomization~* History of more than two UTIs prior to randomization~* For patients less than 6 months of age at randomization, gestational age less than 34 weeks~* Co-morbid urologic anomalies~* Hydronephrosis, SFU Grade 4~* Ureterocele~* Urethral valve~* Solitary kidney~* Profoundly decreased renal size unilaterally on ultrasound (based on 2 standard deviations below the mean for age and length) performed within 112 days after diagnosis of index UTI~* Multicystic dysplastic kidney~* Neurogenic bladder~* Pelvic kidney or fused kidney~* Known sulfa allergy, inadequate renal or hepatic function, Glucose-6-phosphate dehydrogenase deficiency or other conditions that are contraindications for use of TMP-SMZ~* History of other renal injury/disease~* Unable to complete the study protocol~* Congenital or acquired immunodeficiency~* Underlying anomalies or chronic diseases that could potentially interfere with response to therapy such as chronic gastrointestinal conditions (i.e., malabsorption, inflammatory bowel disease), liver or kidney failure, or malignancy.~* Complex cardiac disease as defined in the Manual of Procedures.~* Any known syndromes associated with VUR or bladder dysfunction~* Index UTI not successfully treated~* Unlikely to complete follow-up~* Family history of anaphylactic reaction to sulfa medications

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 71 Months
- Healthy Volunteers: f

Study Arms:
- Trimethoprim-Sulfamethoxazole (Type: ACTIVE_COMPARATOR): Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.
- Placebo (Type: PLACEBO_COMPARATOR): Cherry-flavored liquid suspension matched to active comparator.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete